SM 5887 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

small and small-cell lung cancers. Amrubicin, a completely synthetic anthracycline derivative, mediates its growth inhibitory action via topoisomerase II inhibition. It is activated in viva by the formation of its 13-OH metabolite, amrubicinol, via reaction with carbonyl reductase. In contrast to doxorubicin and daunorubicin whose metabolites are inactive in the blood, amrubicinol is 10-100 fold more cytotoxic than amrubicin. In phase II clinical trials, amrubicin showed antitumor activity against non-small-cell lung cancers (response rate exceeding 20%) and against untreated extensive stage small-cell-lung cancers (response rate 78.8%). Amrubicin demonstrated a smaller distribution-volume, a shorter half-life in mice and also less chronic cardiotoxicity in preclinical studies compared to doxorubicin. Amrubicin was generally well tolerated with major adverse events being anaemia, leucopenia, thrombocytopenia and neutropenia.

Originator

Sumitomo (Japan)

Trademarks

Calsed

SM 5887 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

SM 5887 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Zibo Hangyu Biotechnology Development Co., Ltd	+86-0533-2185556 +8617865335152	Mandy@hangyubiotech.com	China	10986	58
MedChemexpress LLC	021-58955995	sales@medchemexpress.cn	United States	4861	58
BOC Sciences	16314854226	info@bocsci.com	United States	9923	65
Musechem	+1-800-259-7612	info@musechem.com	United States	4660	60
Shenzhen Botel Biotechnology Co. Ltd.	0755-22202135 13316968096	1979313431@qq.com	China	9033	58
Beijing xinyanhui pharmaceutical research and development co., LTD	13969155946	1461866103@qq.com	China	16111	58
Absin Bioscience Inc.	021-38015121 15000105423	wulan@absin.cn	China	24731	58
Hubei Xinyang Medical Technology Co., Ltd	15347293736 15347293736	2853117764@qq.com	China	8612	58
Nantong QuanYi Biotechnology Co., Ltd	0513-66337626 18051384581	sales@chemhifuture.com	China	4988	58
Jiangsu Aikon Biopharmaceutical R&D co.,Ltd.	025-66113011 18112977050	cb5@aikonchem.com	China	10526	58

---

• SM 5887
• (7S,9S)-9-Acetyl-9-amino-7-(2-deoxy-β-D-erythro-pentopyranosyloxy)-6,11-dihydroxy-5,7,8,9,10,12-hexahydro-5,12-naphthacenedione·hydrochloride
• Amrubicin hydrochloride
• (1S,3S)-3-Acetyl-3-amino-5,12-dihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-tetracenyl2-deoxy-β-D-erythro-pentopyranosidehydrochloride(1:1)
• AMR hydrochloride
• BHMLHEQFWVQAJS-IERVSNJOSA-N
• Calsed
• 110311-30-3